We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close


Bristol-Myers’ $74B Celgene Buy Gives 2019 M&A Fast Start

Law360 (January 3, 2019, 7:16 PM EST) -- Deal-making roared just three days into the New Year as Bristol-Myers Squibb's $74 billion cash-and-stock megadeal for biopharmaceutical company Celgene carried a price tag bigger than last year's largest deal despite...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.